145 related articles for article (PubMed ID: 36186882)
1. Gender differences in the antianhedonic effects of repeated ketamine infusions in patients with depression.
Zheng W; Yang XH; Gu LM; Tan JQ; Zhou YL; Wang CY; Ning YP
Front Psychiatry; 2022; 13():981981. PubMed ID: 36186882
[TBL] [Abstract][Full Text] [Related]
2. Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression.
Zheng W; Yang XH; Gu LM; Tan JQ; Zhou YL; Wang CY; Ning YP
J Affect Disord; 2022 Sep; 313():72-76. PubMed ID: 35772627
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.
Zheng W; Gu LM; Sun CH; Zhou YL; Wang CY; Lan XF; Zhang B; Ning YP
J Affect Disord; 2022 Mar; 300():109-113. PubMed ID: 34965393
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the antianhedonic effects of repeated ketamine infusions in melancholic and non-melancholic depression.
Zheng W; Yang XH; Gu LM; Tan JQ; Zhou YL; Wang CY; Ning YP
Front Psychiatry; 2022; 13():1033019. PubMed ID: 36620669
[TBL] [Abstract][Full Text] [Related]
5. Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder.
Zheng W; Gu L; Zhou Y; Wang C; Lan X; Zhang B; Li Z; Ning Y
Curr Neuropharmacol; 2023; 21(4):1013-1021. PubMed ID: 36173064
[TBL] [Abstract][Full Text] [Related]
6. Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.
Zheng W; Gu LM; Yang XH; Zhou YL; Wang CY; Lan XF; Zhang B; Ning YP
Int J Psychiatry Clin Pract; 2023 Jun; 27(2):145-150. PubMed ID: 36309806
[TBL] [Abstract][Full Text] [Related]
7. Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression.
Zheng W; Gu LM; Zhou YL; Wang CY; Lan XF; Zhang B; Shi HS; Wang DF; Ning YP
Front Psychiatry; 2021; 12():780975. PubMed ID: 34925104
[No Abstract] [Full Text] [Related]
8. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Lan XF; Zhang B; Ning YP
J Affect Disord; 2020 Oct; 275():38-43. PubMed ID: 32658821
[TBL] [Abstract][Full Text] [Related]
9. Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression.
Wilkowska A; Wiglusz MS; Gałuszko-Wegielnik M; Włodarczyk A; Cubała WJ
Front Psychiatry; 2021; 12():704330. PubMed ID: 34733182
[TBL] [Abstract][Full Text] [Related]
10. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
[TBL] [Abstract][Full Text] [Related]
11. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
12. Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression.
Kwaśny A; Cubała WJ; Włodarczyk A
Front Psychiatry; 2024; 15():1334293. PubMed ID: 38439794
[TBL] [Abstract][Full Text] [Related]
13. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
[TBL] [Abstract][Full Text] [Related]
14. Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study.
Liu W; Zhou Y; Wang C; Zheng W; Zhan Y; Lan X; Zhang B; Li H; Chen L; Li M; Ning Y
J Affect Disord; 2020 Jun; 271():1-8. PubMed ID: 32312692
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
[TBL] [Abstract][Full Text] [Related]
16. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychopharmacol; 2019 Apr; 33(4):494-501. PubMed ID: 30789302
[TBL] [Abstract][Full Text] [Related]
17. Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials.
Chen MH; Wu HJ; Li CT; Lin WC; Tsai SJ; Hong CJ; Tu PC; Bai YM; Mao WC; Su TP
J Psychiatr Res; 2021 Dec; 144():448-454. PubMed ID: 34752941
[TBL] [Abstract][Full Text] [Related]
18. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Ibrahim L; Diazgranados N; Franco-Chaves J; Brutsche N; Henter ID; Kronstein P; Moaddel R; Wainer I; Luckenbaugh DA; Manji HK; Zarate CA
Neuropsychopharmacology; 2012 May; 37(6):1526-33. PubMed ID: 22298121
[TBL] [Abstract][Full Text] [Related]
19. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
